Literature DB >> 14743260

Carvedilol: an effective antihypertensive drug with antiischemic/antioxidant cardioprotective properties.

X Rabasseda1.   

Abstract

Carvedilol is a multiple-action drug with alpha(1)- and beta-adrenergic receptor antagonistic, calcium channel blocker and antioxidant activities especially useful in the treatment of hypertension. The antioxidant activity of the drug depends on the carbazole moiety, which is unique to carvedilol and is also present in some of the metabolites lacking either the alpha(1)- or beta-adrenergic receptor blocking activity. These antioxidant properties account for the exceptional ability of carvedilol to reduce cardiac necrosis in animal models of myocardial infarction, as well as its neuroprotective activities in in vivo and in vitro models of brain ischemia. A further property of carvedilol is its ability to inhibit vascular smooth muscle cell migration and proliferation, and neointima formation, after vascular injuries. The identification of all these activities of carvedilol indicates that it is a singular multiple-action antihypertensive agent with potential for cardiovascular organ protection beyond the normalization of high blood pressure.

Entities:  

Year:  1998        PMID: 14743260     DOI: 10.1358/dot.1998.34.11.487475

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  3 in total

1.  Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.

Authors:  Pattipati S Naidu; Amanpreet Singh; Shrinivas K Kulkarni
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

2.  Oxidative stress induced by the Fe/ascorbic acid system or model ischemia in vitro: effect of carvedilol and pyridoindole antioxidant SMe1EC2 in young and adult rat brain tissue.

Authors:  Zdenka Gáspárová; Olga Ondrejičková; Alena Gajdošíková; Andrej Gajdošík; Vladimír Snirc; Svorad Stolc
Journal:  Interdiscip Toxicol       Date:  2010-12

3.  Effect of antihypertensive medications on thrombolysis therapy and outcomes in acute ischemic stroke patients.

Authors:  Tyler Fleming; Brice Blum; Benjamin Averkamp; James Sullivan; Thomas Nathaniel
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-01-23       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.